To find promising hits we offer diverse screening platforms combined with chemoinformatics and medicinal chemistry supported by artificial intelligence.
A priori selection | fragment screening | covalent screening | DNA encoded libraries
Hit to lead
We refine selected hits to design potent and selective analogs. To reduce the attrition rate, we use a combination of comprehensive drug discovery capabilities focusing on physicochemical properties to design druggable compounds.
Lead compounds need to satisfy the target product profile criteria. Medicinal chemists contribute to the evolution of the project improving potency and selectivity, minimizing toxicity, finding the best physicochemical properties. Compound access is supported by scalable production processes.